Research Article

Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study

Table 1

Comparison of clinical characteristics between group 0 () and group 1 ().

CharacteristicGroup 0 ()Group 1 ()2OR (95% CI) value

Age, years, 0.010.732
Sex (male), (%)157 (65.69)68 (71.58)1.32 (0.79, 2.24)0.366
BMI, 0.010.686
Cirrhosis (Y/N), (%)21 (8.79)53 (55.79)12.91 (7.15, 24.09)0.001
Comorbidity
 Diabetes, (%)24 (10.04)7 (7.37)0.73 (0.28, 1.68)0.535
 Hypertension, (%)14 (5.86)8 (8.42)1.49 (0.57, 3.64)0.464
 Ulcer, (%)22 (9.21)16 (16.84)2 (0.98, 4)0.057
HBV-HCV coinfection, (%)5 (2.09)55 (57.89)61.49 (25.24, 187.94)0.001
 Malignancy (not including HCC)8 (3.35)3 (3.16)0.98 (0.2, 3.53)1
Drug regimen
 SOF/LDV, (%)155 (64.85)66 (69.47)1.24 (0.75, 2.08)0.445
 SOF/VEL, (%)83 (34.73)30 (31.58)0.87 (0.52, 1.44)0.611
Reach RVR, (%)118 (49.37)5 (5.26)0.06 (0.02, 0.14)0.001
FIB-4 score, 0.430.001
Baseline AST (U/L), 0.200.001
Baseline ALP (U/L), 0.220.001
Baseline total bilirubin (mg/dl), 0.010.368
Baseline serum creatinine, (μmol/L), 0.010.154
Baseline GFR (mL/min), mean ± SD0.010.896
Baseline hemoglobin (g/L), mean ± SD0.110.001
Baseline viral load log10 IU/ml, 0.100.001
Viral C genotype
 Genotype 1, (%)48 (20.08)74 (77.89)13.82 (7.86, 25.2)0.001
 Genotype 2, (%)25 (10.46)9 (9.47)0.91 (0.39, 1.97)1
 Genotype 3, (%)17 (7.11)5 (5.26)0.75 (0.24, 1.96)0.632
 Genotype 6, (%)149 (62.34)7 (7.37)0.05 (0.02, 0.11)0.001

BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; RVR, rapid virological response; LDV/SOF, ledipasvir/sofosbuvir; VEL/SOF: sofosbuvir/velpatasvir; AST: aspartate aminotransferase; ALT: alanine transaminase; FIB-4: fibrosis index based on four factors; GFR: glomerular filtration rate.